Today: 2 July 2026
Browse Category

NYSE:PFE 17 December 2025 - 25 December 2025

Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer Inc. heads into Christmas Day with investors digesting a dense run of December headlines: a 2026 outlook that came in below Wall Street expectations, ongoing restructuring and cost-cutting, fresh U.S. drug-pricing initiatives that could reshape the industry’s economics, and multiple pipeline updates spanning oncology, immunology and cardiometabolic disease. U.S. markets are closed on Thursday, Dec. 25, 2025, but Pfizer shares last traded on Wednesday, Dec. 24 at $25.03, after moving between $24.90 and $25.14 intraday, according to the latest available pricing data.
25 December 2025
···
Pfizer Stock (PFE) After Hours Today, Dec. 24, 2025: Why Shares Rose in the Christmas Eve Session and What to Watch Before the Next Market Open

Pfizer Stock (PFE) After Hours Today, Dec. 24, 2025: Why Shares Rose in the Christmas Eve Session and What to Watch Before the Next Market Open

Pfizer, Inc. ended the trading day higher on Wednesday, December 24, 2025—an early-close session for U.S. equities ahead of Christmas—before holding essentially flat in after-hours trading. The move may look modest on the surface, but it lands at a moment when Pfizer’s stock narrative is unusually “headline-sensitive”: investors are balancing near-term safety scrutiny around a newly approved hemophilia medicine, management’s fresh 2026 outlook, and the longer-running debate over how Pfizer bridges a looming patent cliff with an oncology- and obesity-focused pipeline.
24 December 2025
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer Inc. stock is spending Christmas Eve in the familiar “mid-$20s” zone — a level that has become a psychological battleground for investors trying to decide whether Pfizer is a high-yield value play, a turnaround story, or simply a “show-me” stock until growth returns. As of Dec. 24, 2025, Pfizer shares were trading around $25 in holiday-thinned markets, leaving the company with a market capitalization of roughly $142 billion and keeping the conversation laser-focused on one question: Can Pfizer rebuild durable growth after the COVID-era revenue boom — and ahead of a looming patent cliff and intensifying U.S. drug-pricing pressure? StockAnalysis
24 December 2025
···
Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

NEW YORK — Pfizer Inc. is heading into the year-end stretch with investors juggling two competing storylines: near-term pressure from fading COVID-era sales and looming patent expirations, versus a long-term rebuild powered by oncology, internal medicine, and a refreshed pipeline strategy. In holiday-thinned trading on December 24, 2025, Pfizer shares were around $24.93. That “mid‑$20s” level matters because it has become the market’s psychological waiting room: bulls see a discounted global pharma franchise with a large dividend and multiple pipeline shots on goal; bears see a company still searching for its next era-defining growth engine.
24 December 2025
·
Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer ended Tuesday’s session lower, then steadied in extended trading as investors digested a late-day safety headline tied to its hemophilia medicine Hympavzi. After-hours snapshot: PFE traded around $24.92, up about 0.16% in after-hours action, after closing the regular session at $24.88. Yahoo FinanceDuring Tuesday’s regular session, PFE ranged roughly between $24.84 and $25.34 with volume near 43.7 million shares.
24 December 2025
··
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Dec. 23, 2025 — Pfizer Inc. stock is ending 2025 in a familiar tug-of-war: a high-yield “value” profile on the one hand, and lingering uncertainty about the company’s post‑COVID growth engine on the other. Shares were trading around $25.15 on Tuesday, keeping the stock in the mid‑$20s range that’s defined much of its recent tape. Today’s news flow adds another variable for investors to price: a safety-related update tied to Pfizer’s hemophilia therapy Hympavzi, landing just as Wall Street digests Pfizer’s newly issued 2026 outlook and the company’s longer road back to growth.
23 December 2025
···
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

As of Monday, December 22, 2025, Pfizer is once again at the center of a familiar market debate: is this a battered pharma giant destined to stay “dead money,” or a dividend-rich turnaround story that could surprise investors as its pipeline matures? The short-term reality is tough to miss. Pfizer has guided to flat-to-down revenue in 2026, with continued COVID-franchise erosion and an accelerating loss-of-exclusivity cycle. But the longer-term case—outlined in a wave of investor and analyst commentary this month—rests on whether Pfizer can execute in the two areas that matter most to its post-patent-cliff future: oncology and obesity/cardiometabolic medicine. Seeking Alpha+3Pfizer+3Reuters+3
22 December 2025
····
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Inc. is heading into 2026 with a familiar mix of strengths and stress fractures: a fortress-scale commercial footprint and one of Big Pharma’s deepest development machines—paired with fading COVID-era revenue, looming loss-of-exclusivity headwinds, and heightened political pressure on U.S. drug pricing. As of the most recent close, Pfizer stock finished around $25.19, leaving shares squarely in the “mid‑$20s” range where they’ve been pinned for much of the post-pandemic reset. MarketBeat+1
21 December 2025
··
Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Dec. 21, 2025 — Pfizer Inc. ends the week in the spotlight after management laid out a 2026 outlook that undershot some Wall Street expectations, while a string of pipeline updates, partnerships, and policy headlines reshaped the near-term narrative around the long-time pharma bellwether. Reuters+1 Pfizer stock last closed at $25.25 on Friday, Dec. 19, with investors weighing whether the company’s cost-cutting and deal-making can offset the twin headwinds of fading COVID-era revenue and a looming patent cliff. Yahoo Finance+1
21 December 2025
··
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer’s stock is ending 2025 in a familiar place: caught between near-term headwinds and a late-decade recovery narrative built around oncology, obesity, and pipeline execution. As of the latest available trade/close data around Dec. 20, Pfizer shares are near $25.19, modestly higher on the most recent session. Investing.com
21 December 2025
····
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Inc. stock is ending the week in a familiar place: the mid-$20s. But the story behind that “quiet” price is anything but quiet. Investors are weighing Pfizer’s newly issued 2026 outlook, an evolving U.S. drug-pricing landscape tied to the TrumpRx / most-favored-nation framework, and a pipeline-and-deal strategy meant to carry the company through a multi-year patent cliff and the long fade of COVID-era revenue. Reuters+1 With U.S. markets closed for the weekend, the latest available quote has Pfizer shares around $25.19, after a volatile stretch that included a sharp selloff earlier in the week following guidance updates. Recent trading showed an intraday range roughly between $24.99 and $25.52, alongside heavy volume. StockAnalysis
20 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Inc. is ending the week with investors weighing a cautious 2026 outlook against fresh pipeline momentum and a fast-moving U.S. drug-pricing policy backdrop. As of the latest available quote on Friday, Dec. 19, 2025, Pfizer shares traded around $25.37, up about 1.3% on the day, with an intraday range of roughly $24.99 to $25.52 and volume near 43.5 million shares. Below is what’s driving Pfizer stock right now, what management and analysts are forecasting, and what catalysts investors are watching into 2026.
19 December 2025
··
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Inc. stock was essentially flat on Friday, Dec. 19, 2025, trading around $25.04 in midday trading, after a volatile week that blended policy headlines, a reset of near-term financial expectations, and fresh pipeline updates. For investors, the story around Pfizer stock right now is less about a single headline and more about a three-way tug-of-war:
19 December 2025
···
Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Inc. ended Thursday’s session essentially flat and stayed steady in after-hours trading, a sign that investors are still digesting the company’s newly issued 2026 outlook while watching a fast-evolving U.S. policy backdrop around drug pricing. As of early evening in New York, Pfizer shares were hovering around $25.05 in after-hours trading, after finishing the regular session at $25.04. Google
19 December 2025
··
Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Analyst Price Targets, Medicare Pricing Pressure, and Pipeline Catalysts (Dec. 18, 2025)

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Analyst Price Targets, Medicare Pricing Pressure, and Pipeline Catalysts (Dec. 18, 2025)

Pfizer stock is trying to regain its footing on Thursday, December 18, 2025, after a volatile mid-December stretch that put the spotlight back on three recurring themes for shareholders: the post-COVID revenue reset, looming loss-of-exclusivity headwinds, and whether Pfizer’s rebuilt pipeline can drive durable growth later this decade. As of 18:26 UTC on Dec. 18, Pfizer shares traded around $25.04, essentially flat on the day.
18 December 2025
Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend, and Key Catalysts

Pfizer Inc. stock is trying to steady itself in late December after a volatile stretch driven by one big theme: the post-COVID hangover is still real, and 2026 is shaping up as another “rebuild” year—even as Pfizer spends aggressively to reload its pipeline. As of Thursday, Dec. 18, 2025, Pfizer shares traded around $25.04, down about 1.8% from the prior close, according to the latest available trade time in the market feed.
18 December 2025
··
Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer Stock (PFE) After Hours Today (Dec. 17, 2025): What to Know Before the Market Opens Thursday

Pfizer finished Wednesday’s session lower and traded only modestly in the after-hours market—an indication that investors are still digesting the company’s newly issued 2026 outlook while weighing fresh pipeline headlines and looming U.S. policy risk around drug pricing. Below is a detailed look at where Pfizer stock stands after the bell on Dec. 17, 2025, what news moved the narrative today, where Wall Street’s forecasts are landing, and what to watch before the opening bell Thursday, Dec. 18, 2025.
18 December 2025
··
Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer Stock (PFE) Today: 2026 Guidance Triggers Fresh Scrutiny—News, Forecasts, Analyst Targets and Dividend Outlook (Dec. 17, 2025)

Pfizer Inc. stock is back in the spotlight on Wednesday, December 17, 2025, as investors digest the drugmaker’s newly issued 2026 outlook, a revised 2025 revenue view, and a longer runway to sustained growth than some shareholders had hoped for. Shares were trading around the mid-$25 range today, following a sharp reaction to the guidance update earlier this week. The big question now: is Pfizer stock a high-yield value play that’s building a post-COVID, post-patent-cliff pipeline—or a “show me” story that will remain range-bound until revenue growth becomes visible?
17 December 2025
···
Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025

Pfizer Stock (PFE) Slips After 2026 Outlook: Guidance, Analyst Forecasts, Dividend Update, and Key Catalysts to Watch on Dec. 17, 2025

Pfizer Inc. is back in the spotlight on Wednesday, Dec. 17, 2025, as investors digest a fresh set of financial targets for 2026, updated 2025 revenue expectations, and a growing pile of “what matters next” questions about the company’s post-COVID trajectory. In late-morning trading, Pfizer stock hovered around $25.53, down about 3.4% on the day, reflecting a cautious market reaction to management’s outlook and the company’s longer roadmap through a multi-year patent-expiration cycle.
17 December 2025
···
Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Earnings Forecasts, Analyst Price Targets and Key Catalysts

December 17, 2025 Pfizer Inc. stock is back in the spotlight on December 17 as investors digest the company’s newly issued full-year 2026 financial guidance, along with a stack of fresh reporting and analyst commentary about what comes next for one of the world’s biggest drugmakers. The immediate market reaction has been skeptical: Pfizer’s outlook points to another year of flat-to-down top-line performance as COVID-era revenue continues to normalize and a looming loss-of-exclusivity cycle begins to bite harder. Pfizer+1
17 December 2025
····
1 … 4 5 6 7 8 … 11

Stock Market Today

  • ASX Seen Lower as Oil Falls on US-Iran Talks; Northern Star Resources Holds to Gold Sales Goal
    July 1, 2026, 9:04 PM EDT. Australian stocks look set to open down Thursday with oil slipping over 1% to the lowest since March after progress in US-Iran talks eased concerns over supply. Northern Star Resources kept its fiscal 2026 gold sales target, giving the mining sector a steadier footing while the broader market weakens. Investors remain cautious, watching commodity moves as geopolitical headlines hit sentiment.
Go toTop